2015-2018年中国深圳乙肝病毒感染率

StephenW

Sci Rep. 2019 Sep 26;9(1):13948. doi: 10.1038/s41598-019-50173-5.
Prevalence of Hepatitis B Virus Infection in Shenzhen, China, 2015-2018.
Tao J1, Zhang W2, Yue H2, Zhu G3, Wu W2, Gong W2, Fang H2, He G2, Hu X2, Zhao H2, Liu A2.
Author information

1
    Department of Laboratory Medicine, Shenzhen People's Hospital, Second Clinical Medical College of Ji'nan University, 1017 Dongmenbei Road, Luohu District, Shenzhen, Guangdong, 518020, China. [email protected].
2
    Department of Laboratory Medicine, Shenzhen People's Hospital, Second Clinical Medical College of Ji'nan University, 1017 Dongmenbei Road, Luohu District, Shenzhen, Guangdong, 518020, China.
3
    School of Information Technology and Electrical Engineering, University of Queensland, Brisbane, QLD, 4067, Australia.

Abstract

China has nearly 10% of the general HBV carrier population in the world; this infection is the most common cause of chronic liver disease. Understanding HBV epidemiology is essential for future infection control, evaluation, and treatment. This study determined the prevalence of HBV infection in Shenzhen by serological testing and analysis in 282,166 HBV screening cases for the following: HBcAb, indicative of previous HBV infection; HBsAg, indicative of chronic (current) infection; HBsAb, indicative of immunity from vaccination; and 34,368 HBV etiological screening cases for HBV-DNA, indicative of virus carriage, in which 1,204 cases were genotyped and mutation analyzed for drug-resistance evaluation. Shenzhen was a highly endemic area of HBV throughout the study period (prevalence 9.69%). HBV infections were almost entirely in the 20 and older age groups with a male-to-female ratio of 1.16:1 which is approximately the same as the male-to-female ratio of the general population in China. However, only 71.25% of the general population retained HBV immune protection. Genotype B and C were identified as the most common agents; recombinant B/C and B/D also existed; some cases, however, could not be genotyped. NAs resistant mutation occurrence patterns were multitudinous; single mutation patterns of rtM204I/V and rtL180M occurrences accounted for majority, followed by the combinational mutation pattern L180M + M204I/V. Drug-resistance was prevalent, mainly occurring in the cross resistance patterns LAM + LdT and LAM + LdT + ETV, and significantly more critical in males. These results demonstrate that all people free from HBV infection should obtain injections of the vaccine or booster shots, and conventional virologic detection in a clinical laboratory center should incorporate genotype and mutation alongside the serological factors for etiology and develop better classification methods, such as sequencing.

PMID:
    31558731
DOI:
    10.1038/s41598-019-50173-5

StephenW

Sci Rep.2019 Sep 26; 9（1）：13948。 doi：10.1038 / s41598-019-50173-5。
2015-2018年中国深圳乙肝病毒感染率
陶J1，张W2，岳H2，朱G3，吴W2，龚W2，方H2，何G2，胡X2，赵H2，刘A2。
作者信息

1
    暨南大学第二临床医学院深圳人民医院检验医学科，广东省深圳市罗湖区东门北路1017号，广东深圳518020 [email protected]。
2
    暨南大学第二临床医学院深圳人民医院检验医学科，广东省深圳市罗湖区东门北路1017号，广东深圳518020
3
    昆士兰大学布里斯班昆士兰大学信息技术与电气工程学院，澳大利亚4067。

抽象

中国占全球HBV携带者总数的近10％；这种感染是慢性肝病的最常见原因。了解HBV流行病学对于将来的感染控制，评估和治疗至关重要。本研究通过血清学检测和分析确定了282,166例HBV筛查病例中深圳的HBV感染率，这些病例包括：HBcAb，表明以前有HBV感染； HBsAg，指示慢性（当前）感染； HBsAb，表明可以免疫接种；对34,368例HBV-DNA的HBV病原学筛查病例表明有病毒携带，其中对1,204例病例进行了基因分型并进行了突变分析以进行耐药性评估。在整个研究期间，深圳都是HBV的高度流行地区（患病率9.69％）。 HBV感染几乎完全发生在20岁及以上年龄组，男女比例为1.16：1，与中国普通人群的男女比例大致相同。但是，只有71.25％的普通人群保留了HBV免疫保护。基因型B和C被确定为最常见的病原体。还存在重组B / C和B / D；但是，有些情况无法进行基因分型。 NAs耐药突变的发生方式是多种多样的。 rtM204I / V的单突变型和rtL180M的发​​生占多数，其次是组合突变型L180M + M204I / V。耐药性普遍存在，主要发生在交叉耐药模式LAM + + LdT和LAM + + LdT + + ETV中，并且在男性中更为重要。这些结果表明，所有不受HBV感染的人都应注射疫苗或加强注射，临床实验室的常规病毒学检测应将基因型和突变与病因学的血清学因素相结合，并开发更好的分类方法，例如测序。

结论：
    31558731
DOI：
    10.1038 / s41598-019-50173-5